

ZERO - The End of Prostate Cancer

Financial Statements
and Independent Auditors' Report

December 31, 2014 and 2013

ZERO - The End of Prostate Cancer

Financial Statements
December 31, 2014 and 2013

Contents

Independent Auditors' Report.....	1-2
<i>Financial Statements</i>	
Statements of Financial Position.....	3
Statements of Activities	4-5
Statements of Cash Flows.....	6
Notes to Financial Statements.....	7-16
<i>Supplemental Information</i>	
Schedules of Functional Expenses.....	17-18

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
ZERO - The End of Prostate Cancer

We have audited the accompanying financial statements of ZERO - The End of Prostate Cancer ("ZERO"), which comprise the statement of financial position as of December 31, 2014, the related statements of activities and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ZERO as of December 31, 2014, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matters

The financial statements of ZERO as of December 31, 2013, were audited by other auditors whose report, dated March 12, 2014, expressed an unmodified opinion on those statements.

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The supplemental information included on page 17 is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole. The information for the year ended December 31, 2013 on page 18 was audited as part of the basic financial statements by other auditors whose report, dated March 12, 2014, expressed an unmodified opinion on those financial statements.



Vienna, Virginia
April 7, 2015

ZERO - The End of Prostate Cancer

Statements of Financial Position December 31, 2014 and 2013

	2014	2013
Assets		
Current assets:		
Cash and cash equivalents	\$ 3,354,484	\$ 2,272,151
Contributions receivable	25,043,035	30,115,324
Prepaid expenses	96,365	143,003
Employee receivable and other receivable	2,744	1,892
	<hr/>	<hr/>
Total current assets	28,496,628	32,532,370
Investments	837,997	818,032
Property and equipment, net	121,621	263,716
Security deposit	7,213	6,378
	<hr/>	<hr/>
Total assets	<u>\$ 29,463,459</u>	<u>\$ 33,620,496</u>
Liabilities and Net Assets		
Liabilities		
Current liabilities:		
Accounts payable and accrued expenses	\$ 175,140	\$ 144,096
Grants payable	27,031,571	31,255,587
	<hr/>	<hr/>
Total current liabilities	27,206,711	31,399,683
Deferred rent	31,663	31,122
	<hr/>	<hr/>
Total liabilities	<u>27,238,374</u>	<u>31,430,805</u>
Net Assets		
Unrestricted	1,162,085	1,226,268
Temporarily restricted	1,063,000	963,423
	<hr/>	<hr/>
Total net assets	<u>2,225,085</u>	<u>2,189,691</u>
Total liabilities and net assets	<u>\$ 29,463,459</u>	<u>\$ 33,620,496</u>

ZERO - The End of Prostate Cancer

Statement of Activities
For the Year Ended December 31, 2014

	Unrestricted	Temporarily Restricted	Total
Revenue and Support			
Grants and contributions	\$ 27,343,301	\$ 1,200,338	\$ 28,543,639
In-kind contributions	554,955	-	554,955
Special events	133,071	-	133,071
Interest and dividends	25,135	-	25,135
Gain on investments	6,393	-	6,393
Merchandise sales	34,497	-	34,497
Net assets released from restrictions	1,100,761	(1,100,761)	-
Total revenue and support	29,198,113	99,577	29,297,690
Expenses			
Program services:			
Patient support	24,234,356	-	24,234,356
Research and awareness	3,855,963	-	3,855,963
Advocacy	329,002	-	329,002
Total program services	28,419,321	-	28,419,321
Supporting services:			
Management and general	332,534	-	332,534
Fundraising	436,149	-	436,149
Special events	74,292	-	74,292
Total supporting services	842,975	-	842,975
Total expenses	29,262,296	-	29,262,296
Change in Net Assets	(64,183)	99,577	35,394
Net Assets, beginning of year	1,226,268	963,423	2,189,691
Net Assets, end of year	\$ 1,162,085	\$ 1,063,000	\$ 2,225,085

See accompanying notes.

ZERO - The End of Prostate Cancer

Statement of Activities
For the Year Ended December 31, 2013

	Unrestricted	Temporarily Restricted	Total
Revenue and Support			
Grants and contributions	\$ 46,938,438	\$ 887,993	\$ 47,826,431
In-kind contributions	705,822	-	705,822
Special events	265,665	-	265,665
Interest and dividends	13,512	-	13,512
Gain on investments	57,195	-	57,195
Merchandise sales	2,802	-	2,802
Net assets released from restrictions	118,048	(118,048)	-
Total revenue and support	48,101,482	769,945	48,871,427
Expenses			
Program services:			
Patient support	42,805,688	-	42,805,688
Research and awareness	3,029,287	-	3,029,287
Advocacy	510,854	-	510,854
Total program services	46,345,829	-	46,345,829
Supporting services:			
Management and general	399,078	-	399,078
Fundraising	267,661	-	267,661
Special events	136,195	-	136,195
Total supporting services	802,934	-	802,934
Total expenses	47,148,763	-	47,148,763
Change in Net Assets	952,719	769,945	1,722,664
Net Assets, beginning of year	273,549	193,478	467,027
Net Assets, end of year	\$ 1,226,268	\$ 963,423	\$ 2,189,691

See accompanying notes.

ZERO - The End of Prostate Cancer

Statements of Cash Flows For the Years Ended December 31, 2014 and 2013

	2014	2013
Cash Flows from Operating Activities		
Change in net assets	\$ 35,394	\$ 1,722,664
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Net realized and unrealized gains	(6,393)	(57,195)
Depreciation	93,336	94,228
Loss on disposal	65,471	136
Change in operating assets and liabilities:		
(Increase) decrease in:		
Contributions receivable	5,072,289	(29,960,159)
Employee receivable and other receivable	(852)	3,898
Prepaid expenses	46,638	(91,813)
Security deposit	(835)	-
Increase (decrease) in:		
Accounts payable and accrued expenses	31,044	(110,243)
Grants payable	(4,224,016)	30,988,257
Deferred revenue	-	(17,369)
Deferred rent	541	3,057
	1,112,617	2,575,461
Cash Flows from Investing Activities		
Purchases of property and equipment	(16,712)	(97,011)
Purchases of investments	(16,963)	(408,777)
Proceeds from sales of investments	3,391	400,557
	(30,284)	(105,231)
Cash Flows from Financing Activity		
Principal payments on line of credit	-	(450,000)
	-	(450,000)
Net Increase in Cash and Cash Equivalents	1,082,333	2,020,230
Cash and Cash Equivalents, beginning of year	2,272,151	251,921
Cash and Cash Equivalents, end of year	\$ 3,354,484	\$ 2,272,151
Supplemental Disclosure		
Cash paid for interest	\$ 27	\$ 5,924

See accompanying notes.

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

1. Nature of Operations

Zero - The End of Prostate Cancer (“ZERO”) was formerly known as ZERO - The Project to End Prostate Cancer before changing its name on June 6, 2012. Prior to that date, the organization had been known since May 8, 2008 as National Prostate Cancer Coalition Fund (NPCCF). NPCCF, incorporated under the laws of the District of Columbia on July 7, 1998, was the surviving organization from a merger on December 21, 1998 between NPCCF and National Prostate Cancer Coalition, Inc. (NPCCI), an organization incorporated under the laws of the state of Florida on September 6, 1996.

ZERO’s activities and programs are created to advance research, encourage action, provide patient financial assistance, and promote education and awareness of prostate cancer. Programs are funded primarily through contributions from individuals, foundations, and corporations.

Program Description

ZERO’s mission is to end prostate cancer by protecting federal research dollars and directly funding the most promising prostate cancer research. ZERO will stop the pain and suffering of the disease by educating men and their families, encouraging action, and providing direct financial support to patients. ZERO’s goal is to create Generation ZERO, the first generation of men free from prostate cancer.

ZERO provides comprehensive treatment and education information to patients and their families throughout their prostate cancer journey through ZERO’s website, www.zerocancer.org, a monthly electronic newsletter, and widely distributed videos and printed materials. Through a series of nationwide events including ZERO Prostate Cancer Run/Walk, ZERO Prostate Cancer Golf, ZERO Prostate Cancer Endurance, and the ZERO Prostate Cancer Summit, ZERO is activating the prostate cancer community and increasing research funding while raising awareness and protecting access to care. The ZERO Prostate Cancer Drive, a mobile medical testing program, provides free prostate cancer testing across the U.S. For men with advanced stage prostate cancer, ZERO provides direct copay assistance and education.

2. Summary of Significant Accounting Policies

Basis of Accounting and Presentation

ZERO’s financial statements are prepared on the accrual basis of accounting. Net assets are reported based on the presence or absence of donor-imposed restrictions.

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

2. Summary of Significant Accounting Policies (continued)

Classification of Net Assets

- *Unrestricted net assets* represent funds that are not subject to donor-imposed stipulations and are available for support of ZERO's operations.
- *Temporarily restricted net assets* represent funds subject to donor-imposed restrictions that are met either by actions of ZERO or by the passage of time. Temporarily restricted net assets were \$1,063,000 and \$963,423 at December 31, 2014 and 2013, respectively.

Cash Equivalents

For the purpose of the statements of cash flows, ZERO considers as cash equivalents all highly liquid investments, which can be converted into known amounts of cash and have a maturity period of ninety days or less at the time of purchase. Excluded from this definition of cash equivalents are amounts held in investment portfolios, which are included in investments in the accompanying statements of financial position.

Contributions Receivable

Contributions receivable primarily consist of pledges from corporations, foundations, and individuals. Management expects all contributions receivable to be fully collectible; accordingly, no allowance for doubtful accounts has been established. If management determines the receivable to be uncollectable, it is directly charged off at that time.

All contributions receivable at December 31, 2014 and 2013 are due within one year and are recorded at net realizable value. When contributions are receivable beyond one year, ZERO's policy is to discount those receivables to net present value.

Investments

Investments are recorded at fair value based on quoted market prices. Realized and unrealized gains and losses are reported as a component of investment income in the accompanying statements of activities.

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

2. Summary of Significant Accounting Policies (continued)

Property and Equipment

ZERO capitalizes all property and equipment acquisitions of \$1,000 and above. Property and equipment are carried at cost, if purchased, or fair value at date of donation, if contributed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 3 to 7 years. Expenditures for maintenance and repairs are charged to expenses as incurred.

Revenue Recognition

Contributions are recognized when the donor makes an unconditional promise to give. ZERO reports gifts of cash and other assets as temporarily restricted if they are received with donor stipulations that limit the use of the donated assets. Temporarily restricted net assets are reported as unrestricted net assets if the restrictions are met in the same period received. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statements of activities as net assets released from restrictions. Revenue from all other sources is recognized when earned.

In-Kind Contributions

In-kind contributions consist primarily of advertising, legal fees, promotional items, and meals. These donations are utilized in ZERO's programmatic activities and are recorded at their fair value at the time of donation.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis in the accompanying statements of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

Advertising Expense

ZERO expenses advertising costs as incurred. ZERO spent approximately \$406,000 and \$496,000 on advertising during the years ended December 31, 2014 and 2013, respectively, of which approximately \$372,000 and \$461,000 was donated during the years ended December 31, 2014 and 2013, respectively.

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

2. Summary of Significant Accounting Policies (continued)

Allocation of Joint Costs

For the year ended December 31, 2014, ZERO incurred joint costs of approximately \$178,000 for program events activities that included fundraising appeals. Of those costs, approximately \$149,000 was allocated to program expense, \$17,500 was allocated to fundraising expense and \$11,500 was allocated to management and general.

For the year ended December 31, 2013, ZERO incurred joint costs of approximately \$142,200 for program events activities that included fundraising appeals. Of those costs, approximately \$115,600 was allocated to program expense, \$13,400 was allocated to fundraising expense and \$13,200 was allocated to management and general.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Subsequent Events

In preparing these financial statements, ZERO has evaluated events and transactions for potential recognition or disclosure through April 7, 2015, the date the financial statements were available to be issued.

3. Concentrations

ZERO maintains cash balances at financial institutions in the Washington DC metropolitan area. The accounts at these institutions are insured by the Federal Deposit Insurance Corporation (FDIC) and Securities Investor Protection Corporation (SIPC). At times, deposits exceed federally insured limits. Management believes the risk in these situations to be minimal.

As of December 31, 2014 and 2013, approximately 99% of contributions receivable were due from one donor.

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

3. Concentrations (continued)

During the years ended December 31, 2014 and 2013, approximately \$25,000,000 and \$44,500,000, or 88% and 93%, respectively, of contributions were received from one donor.

4. Investments and Fair Value Measurements

ZERO follows Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, *Fair Value Measurements and Disclosures*, for its financial assets. This standard establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value measurement standards require an entity to maximize the use of observable inputs (such as quoted prices in active markets) and minimize the use of unobservable inputs (such as appraisals or other valuation techniques) to determine fair value. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the entity's perceived risk of that instrument.

The inputs used in measuring fair value are categorized into three levels. Level 1 inputs consist of unadjusted quoted prices in active markets for identical assets and liabilities and have the highest priority. Level 2 is based upon observable inputs other than quoted market prices, and Level 3 is based on unobservable inputs. ZERO recognizes transfers between levels in the fair value hierarchy at the end of the reporting period.

In general, and where applicable, ZERO uses quoted prices in active markets for identical assets to determine fair value. This pricing methodology applies to Level 1 investments.

The following table presents ZERO's fair value hierarchy for those investments measured on a recurring basis at December 31, 2014:

	Level 1	Level 2	Level 3	Total fair value
Cash and money market funds	\$ 53,585	\$ -	\$ -	\$ 53,585
US fixed income - bonds	330,697	-	-	330,697
Mutual funds:				
US large cap	152,247	-	-	152,247
US mid cap	37,700	-	-	37,700
US fixed income	13,196	-	-	13,196
Equities	155,401	-	-	155,401
Alternative assets	95,171	-	-	95,171
Total investments	\$ 837,997	\$ -	\$ -	\$ 837,997

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

4. Investments and Fair Value Measurements (continued)

The following table presents ZERO's fair value hierarchy for those investments measured on a recurring basis at December 31, 2013:

	Level 1	Level 2	Level 3	Total fair value
Cash and money market funds	\$ 55,609	\$ -	\$ -	\$ 55,609
US fixed income - bonds	203,883	-	-	203,883
US fixed income - mutual funds	130,276	-	-	130,276
Foreign exchange	5,769	-	-	5,769
Equities	324,291	-	-	324,291
Mutual funds	98,204	-	-	98,204
Total investments	\$ 818,032	\$ -	\$ -	\$ 818,032

Investment income consists of the following for the years ended December 31:

	2014	2013
Interest and dividends	\$ 25,135	\$ 13,512
Net realized and unrealized gains	6,393	57,195
Total investment income	\$ 31,528	\$ 70,707

5. Property and Equipment

Property and equipment consists of the following at December 31:

	2014	2013
Database	\$ 119,378	\$ 119,378
Furniture and equipment	107,168	137,117
Website	80,700	66,700
Screening vehicle	-	506,723
Total property and equipment	307,246	829,918
Less: accumulated depreciation	(185,625)	(566,202)
Property and equipment, net	\$ 121,621	\$ 263,716

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

6. Temporarily Restricted Net Assets

Temporarily restricted net assets were restricted for the following at December 31:

	<u>2014</u>	<u>2013</u>
Purpose restricted	\$ 1,063,000	\$ 905,271
Time restricted	<u>-</u>	<u>58,152</u>
Total temporarily restricted net assets	<u>\$ 1,063,000</u>	<u>\$ 963,423</u>

Temporarily restricted net assets were released from restrictions as follows for the years ended December 31:

	<u>2014</u>	<u>2013</u>
Purpose restricted	\$ 1,042,609	\$ 55,000
Time restricted	<u>58,152</u>	<u>63,048</u>
Total temporarily restricted net assets released from restrictions	<u>\$ 1,100,761</u>	<u>\$ 118,048</u>

7. Commitments and Contingencies

Operating Lease

ZERO entered into an operating lease for office space, which commenced on August 5, 2009 and expires August 4, 2019. The lease includes an annual escalation clause as defined in the lease agreement. ZERO is responsible for its prorated share of real estate taxes and operating expenses. Under accounting principles generally accepted in the United States of America (GAAP) all rental payments, including fixed rent increases, are recognized on a straight-line basis over the term of the lease. The difference between the GAAP rent expense and the required lease payments is reflected as deferred rent in the accompanying statements of financial position.

On September 1, 2009, ZERO entered into an operating lease agreement for office equipment. The lease term was for 39 months and expires October 31, 2015, requiring monthly payments of \$246.

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

7. Commitments and Contingencies (continued)

Future minimum lease payments under all leases are as follows for the years ending December 31:

2015	\$	94,699
2016		95,003
2017		97,852
2018		100,787
2019		59,808
		<hr/>
Total future minimum lease payments	\$	<u>448,149</u>

Occupancy expense was approximately \$91,000 and \$90,000 for the years ended December 31, 2014 and 2013, respectively.

8. Line of Credit

ZERO has a secured line of credit (LOC) with a bank expiring December 31, 2015. Under the terms of the agreement, ZERO can draw up to a maximum amount of \$500,000 and ZERO may repay the LOC with interest at either the adjusted LIBOR rate plus 2.10% or a fixed rate per annum equal to the offered rate applicable to such LOC. The bank has a security interest in and a lien upon all marketable securities maintained by ZERO at the bank. The LOC is renewed each year. There was no outstanding balance on the LOC at December 31, 2014 and 2013.

9. Retirement Plan

In 2005, ZERO adopted a section 403(b) Retirement Plan (“the Plan”). All regular full-time and part-time employees who work seventeen-and-one-half (17.5) hours or more weekly are eligible to participate in the Plan through salary deferrals. Participation in the Plan begins on the first day of the month following ninety (90) days after the date of hire. ZERO does not contribute to the Plan.

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

10. Consultants

Consultant expenses are allocated as follows for the years ended December 31:

	<u>2014</u>	<u>2013</u>
Programs:		
ZPCC	\$ 342,588	\$ 269,075
Drive Against Prostate Cancer	29,173	9,060
Communications	<u>12,000</u>	<u>94,226</u>
Total programs	383,761	372,361
Fundraising	<u>-</u>	<u>15,015</u>
Total	<u><u>\$ 383,761</u></u>	<u><u>\$ 387,376</u></u>

11. In-Kind Contributions

In-kind contributions consisted of the following for the years ended December 31:

	<u>2014</u>	<u>2013</u>
Advertising	\$ 371,853	\$ 461,264
Gifts and giveaways	80,741	56,590
Legal services	61,681	76,180
Race programs and special events	37,530	110,538
Medical services	<u>3,150</u>	<u>1,250</u>
Total in-kind contributions	<u><u>\$ 554,955</u></u>	<u><u>\$ 705,822</u></u>

12. Patient Assistance Program

During 2013, ZERO established a partnership with another not-for-profit organization to provide assistance for patients being treated for metastatic castrate resistant prostate cancer (“the Program”). For the year ended December 31, 2014, ZERO received contributions of approximately \$25,000,000 and awarded grants of approximately \$24,000,000 related to the Program. For the year ended December 31, 2013, ZERO received contributions of approximately \$44,505,000 and awarded grants of approximately \$42,730,000 related to the Program.

ZERO - The End of Prostate Cancer

Notes to Financial Statements
December 31, 2014 and 2013

13. Income Taxes

ZERO is exempt from federal and state income taxes under Section 501(c)(3) of the Internal Revenue Code (“the Code”). ZERO is, however, subject to income taxes on any unrelated business income. In addition, the Internal Revenue Service (IRS) has determined that ZERO is not a private foundation within the meaning of Section 509(a) of the Code.

Management has evaluated all tax positions and has concluded that ZERO has taken no uncertain tax positions that qualify for either recognition or disclosure in the accompanying financial statements. ZERO files forms 990 in the U.S. federal jurisdiction, and is generally no longer subject to examination by the IRS for years before 2011.

SUPPLEMENTAL INFORMATION

ZERO - The End of Prostate Cancer

Schedule of Functional Expenses
For the Year Ended December 31, 2014

	Program Services				Management and General	Fundraising	Special Events	Total Expenses
	Patient Support	Research and Awareness	Advocacy	Total Program Services				
Salaries	\$ 106,625	\$ 780,511	\$ 204,097	\$ 1,091,233	\$ 219,828	\$ 267,577	\$ -	\$ 1,578,638
Payroll taxes	7,531	54,542	13,712	75,785	15,377	19,492	-	110,654
Benefits	8,775	72,543	11,620	92,938	22,574	18,099	-	133,611
Consultants	-	358,761	25,000	383,761	-	-	-	383,761
Advertising and public relations	33,867	812,231	1,548	847,646	2,244	11,858	-	861,748
Special events expense	-	-	-	-	-	-	74,292	74,292
Printing and publications	-	9,811	-	9,811	2,218	-	-	12,029
Postage	1,959	32,657	31	34,647	1,715	4,010	-	40,372
Travel	1,042	148,909	41,419	191,370	9,919	2,856	-	204,145
Occupancy	-	62,922	-	62,922	12,660	15,314	-	90,896
Equipment and facilities rental	-	115,029	-	115,029	901	1,089	-	117,019
Licenses and permits	-	7,565	-	7,565	-	54	-	7,619
Entry fees	-	117,099	-	117,099	-	-	-	117,099
Insurance	-	39,254	-	39,254	4,890	1,537	-	45,681
Telephone service	-	21,861	9	21,870	4,597	4,417	-	30,884
Repairs and maintenance	-	2,798	-	2,798	1,557	623	-	4,978
Vehicle operating expense	-	14,949	-	14,949	-	-	-	14,949
Depreciation	-	64,611	-	64,611	13,000	15,725	-	93,336
Dues and state registration	-	28,552	20,235	48,787	6,353	40,254	-	95,394
Office supplies	-	18,050	1,019	19,069	6,820	4,026	-	29,915
Professional fees	74,557	154,784	10,000	239,341	5,804	9,019	-	254,164
Bank and credit card fees	-	37,497	136	37,633	527	4,910	-	43,070
Interest expense	-	-	-	-	7	20	-	27
Medical supplies	-	5,801	-	5,801	-	-	-	5,801
Medical testing expense	-	11,485	-	11,485	-	-	-	11,485
Website and database management	-	48,982	176	49,158	735	14,294	-	64,187
Miscellaneous	-	4,009	-	4,009	808	975	-	5,792
Grants	24,000,000	830,750	-	24,830,750	-	-	-	24,830,750
Total Expenses	\$ 24,234,356	\$ 3,855,963	\$ 329,002	\$ 28,419,321	\$ 332,534	\$ 436,149	\$ 74,292	\$ 29,262,296

ZERO - The End of Prostate Cancer

Schedule of Functional Expenses
For the Year Ended December 31, 2013

	Program Services				Management and General	Fundraising	Special Events	Total Expenses
	Patient Support	Research and Awareness	Advocacy	Total Program Services				
Salaries	\$ 42,024	\$ 624,154	\$ 217,747	\$ 883,925	\$ 181,874	\$ 137,174	\$ -	\$ 1,202,973
Payroll taxes	2,709	43,010	15,876	61,595	12,685	9,528	-	83,808
Benefits	3,139	58,268	16,981	78,388	13,824	5,697	-	97,909
Consultants	-	372,361	-	372,361	-	15,015	-	387,376
Advertising and public relations	7,485	813,002	6,438	826,925	7,272	23,911	-	858,108
Special events expense	-	-	-	-	-	-	136,195	136,195
Printing and publications	-	5,807	550	6,357	-	-	-	6,357
Postage	932	23,406	93	24,431	1,705	1,474	-	27,610
Travel	1,425	131,640	227,108	360,173	14,854	18,626	-	393,653
Occupancy	-	65,792	-	65,792	13,956	10,526	-	90,274
Equipment and facilities rental	-	81,879	1,056	82,935	1,933	1,326	-	86,194
Licenses and permits	-	14,052	-	14,052	-	198	-	14,250
Entry fees	-	67,894	-	67,894	-	-	-	67,894
Insurance	-	33,023	-	33,023	1,962	634	-	35,619
Telephone service	-	20,857	21	20,878	4,853	2,768	-	28,499
Repairs and maintenance	-	4,557	33	4,590	2,932	973	-	8,495
Vehicle operating expense	-	19,982	-	19,982	-	-	-	19,982
Depreciation	-	77,949	-	77,949	4,308	11,971	-	94,228
Dues and state registration	-	14,190	18,587	32,777	4,320	9,402	-	46,499
Office supplies	236	5,919	(30)	6,125	4,366	924	-	11,415
Professional fees	17,738	116,404	1,208	135,350	119,474	7,375	-	262,199
Bank and credit card fees	-	34,778	-	34,778	716	2,146	-	37,640
Interest expense	-	4,289	-	4,289	949	686	-	5,924
Medical supplies	-	3,163	-	3,163	-	-	-	3,163
Medical testing expense	-	16,551	-	16,551	-	-	-	16,551
Website and database management	-	55,032	5,186	60,218	2,520	6,824	-	69,562
Miscellaneous	-	3,021	-	3,021	4,575	483	-	8,079
Grants	42,730,000	318,307	-	43,048,307	-	-	-	43,048,307
Total Expenses	\$ 42,805,688	\$ 3,029,287	\$ 510,854	\$ 46,345,829	\$ 399,078	\$ 267,661	\$ 136,195	\$ 47,148,763